Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|March 7, 2017
Intrahepatic Sampling for the Elucidation of Antiviral Clinical PharmacologyCharles S Venuto, Andrew H TalalClinical Pharmacology in Drug Development|March 7, 2017
Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use TreatmentAndrew H Talal, Charles S Venuto, Islam YounisJournal of Clinical and Translational Science|June 30, 2026
Prediction of α-synuclein seed amplification assay positivity in remotely followed <i>LRRK2</i> G2019S carriers using a validated data-driven modelRuth B Schneider, Peggy Auinger, Charles S VenutoJournal of Parkinson'S Disease|May 18, 2020
Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative ParticipantsMonica Javidnia, Ira Shoulson, Karl Kieburtz, et al.Movement Disorders Clinical Practice|October 17, 2022
Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's DiseaseMariam Paracha, Konnor Herbst, Karl Kieburtz, et al.Movement Disorders : Official Journal of the Movement Disorder Society|October 15, 2011
Pharmacologic approaches to the treatment of Huntington's diseaseCharles S Venuto, Andrew McGarry, Qing Ma, et al.Medrxiv : the Preprint Server for Health Sciences|August 16, 2024
Predicting Cerebrospinal Fluid Alpha-Synuclein Seed Amplification Assay Status from Demographics and Clinical DataCharles S Venuto, Konnor Herbst, Lana M Chahine, et al.Neurology Open Access|April 15, 2026
Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical DataCharles S Venuto, Konnor Herbst, Lana Chahine, et al.Clinical and Translational Science|November 8, 2024
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's diseaseEdgar A Bernal, Shu Yang, Konnor Herbst, et al.Clinical Pharmacology in Drug Development|March 7, 2017
Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment MedicationsCindy J Bednasz, Charles S Venuto, Qing Ma, et al.Pageof 4